7,650.25

+36.25

+0.48%

52,089.00

+171.00

+0.33%

28,797.00

+263.00

+0.92%

Russell 2000 Futures

2,837.30

+16.00

+0.57%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,923.60

+24.70

+0.63%

78,078.34

+219.75

+0.28%

Crude Oil Dec 26

100.62

-3.50

-3.36%

US Private Equity

10,850.63

-82.20

-0.75%

NSE - Free Realtime Quote INR

Zydus Lifesciences Limited (ZYDUSLIFE.NS)

1,241.40 -4.10 (-0.33%)

As of 11:49:53 AM GMT+5:30. Market Open.

Loading Chart for ZYDUSLIFE.NS

Chart Range Bar

Interval:

In partnership with ChartIQ

Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA

Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA

Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA

Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA

Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.

Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.

Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.

Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.

Zydus Lifesciences Ltd (BOM:532321) (Q1 2027) Earnings Call Highlights: Robust 66. ...

Zydus Lifesciences Ltd (BOM:532321) (Q1 2027) Earnings Call Highlights: Robust 66. ...

Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027

Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027

Zydus Lifesciences Ltd (BOM:532321) Q4 2026 Earnings Call Highlights: Record Growth and ...

Zydus Lifesciences Ltd (BOM:532321) Q4 2026 Earnings Call Highlights: Record Growth and ...

Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.

Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.

Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal

Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal

Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC

Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC

Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat

Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat

Mobilize your Website

View Site in Mobile | Classic

Share by: